Transcatheter Aortic Valve-in-Valve Replacement for Degenerated Stentless Bioprosthetic Aortic Valves: Results of a Multicenter Retrospective Analysis

The purpose of this study was to evaluate the safety and efficacy of valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) for stentless bioprosthetic aortic valves (SBAVs) and to identify predictors of adverse events. ViV TAVR in SBAVs is associated with unique technical challenges and...

Full description

Saved in:
Bibliographic Details
Published in:JACC. Cardiovascular interventions 2019-07, Vol.12 (13), p.1217-1226
Main Authors: Miller, Matthew, Snyder, Mandy, Horne, Benjamin D, Harkness, James R, Doty, John R, Miner, Edward C, Jones, Kent W, O'Neal, Kelly R, Reid, Bruce B, Caine, William T, Clayson, Stephen E, Lindley, Eric, Gardner, Blake, Connors, Rafe C, Bowles, B Jason, Whisenant, Brian K
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study was to evaluate the safety and efficacy of valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) for stentless bioprosthetic aortic valves (SBAVs) and to identify predictors of adverse events. ViV TAVR in SBAVs is associated with unique technical challenges and risks. Clinical records and computer tomographic scans were retrospectively reviewed for procedural complications, predictors of coronary obstruction, mortality, and echocardiographic results. Among 66 SBAV patients undergoing ViV TAVR, mortality was 2 of 66 patients (3.0%) at 30 days and 5 of 52 patients (9.6%) at 1 year. At 1 year, left ventricular end-systolic dimension was decreased versus baseline (median [interquartile range (IQR)]: 3.0 [2.6 to 3.6] cm vs. 3.7 [3.2 to 4.4] cm; p 
ISSN:1876-7605
DOI:10.1016/j.jcin.2019.05.022